The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a summary-form affirmance, suggesting the panel found the unpatentability determinations below to be well-supported without requiring extensive written opinion. The Basis of Termination is recorded as ‘Unpatentable,’ confirming the outcome is merits-based, not procedural. Under Federal Circuit review, factual findings of unpatentability are reviewed for substantial evidence, and legal conclusions de novo. The absence of a split or partial reversal across six patents is notable and consistent with a strong underlying evidentiary record favouring Amneal.

Any pharmaceutical company, CDMO, or device manufacturer developing albuterol sulfate inhalation aerosol products — or HFA-propellant pMDI platforms more broadly — should review this ruling as part of their freedom-to-operate analysis. While these six patents have been affirmed unpatentable in the Amneal proceedings, FTO clearance requires confirming that no related Teva patents outside this litigation remain asserted, that the unpatentability findings bind Teva in your specific context, and that no continuation applications are pending that could issue with refined claims.

PatSnap Eureka’s FTO Search Agent can map the full Teva albuterol patent family — including continuations, divisionals, and international counterparts — against your specific product formulation and device design. Eureka cross-references litigation outcomes, PTAB decisions, and prosecution history to surface residual risk patents that a standard freedom-to-operate search might miss. For respiratory drug delivery teams, this is the fastest way to confirm whether the Amneal affirmance genuinely clears your path or whether adjacent Teva IP remains a concern.